评论：透皮利伐斯的明对轻中度阿尔茨海默病 ADAS-cog 项目的影响。
Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
机构信息
St Louis University School of Medicine, MO 63104, USA.
出版信息
Am J Alzheimers Dis Other Demen. 2010 Dec;25(8):627-33. doi: 10.1177/1533317510385808.
Alzheimer's disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind, placebo- and active-controlled, 24-week clinical trial, the specific effects of rivastigmine patch on individual ADAS-cog items and cognitive domains (memory, language, and praxis) were explored. The mean baseline to week 24 changes were calculated for each ADAS-cog item and domain in this exploratory, hypothesis-generating analysis. Patients on 9.5 mg/24 h rivastigmine patch, 17.4 mg/24 h rivastigmine patch, and 3 to 12 mg/d rivastigmine capsules showed improvements over placebo on the memory and praxis ADAS-cog subscales. The rivastigmine patch groups also showed improvements on the language subscale. Significant differences versus placebo were seen on several individual item scores in the rivastigmine-treated groups. Rivastigmine patch was associated with improvements on the memory, praxis, and language domains of cognition in patients with mild-to-moderate AD.
阿尔茨海默病（AD）患者接受rivastigmine 透皮贴剂治疗与安慰剂相比在 AD 评估量表认知子量表（ADAS-cog）上有显著统计学差异。在这项为期 24 周的双盲、安慰剂和阳性对照临床试验的回顾性分析中，探索了rivastigmine 贴剂对 ADAS-cog 各单项和认知域（记忆、语言和执行功能）的具体影响。在这项探索性、生成假说的分析中，计算了每个 ADAS-cog 单项和域在基线至 24 周的平均变化。9.5 mg/24 h、17.4 mg/24 h rivastigmine 贴剂和 3 至 12 mg/d rivastigmine 胶囊组的患者在记忆和执行功能 ADAS-cog 子量表上的改善优于安慰剂。rivastigmine 贴剂组在语言子量表上也有改善。在 rivastigmine 治疗组中，几个单项评分与安慰剂相比有显著差异。rivastigmine 贴剂与轻中度 AD 患者认知的记忆、执行功能和语言域的改善相关。
Zotero 插件